It’s official: Roche is a Car-T player
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
EHA 2022 – Caribou’s turn to run into allo Car-T relapses
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
Nkarta: at least as good as Fate, at a tenth of the price
After a long wait, investors at last have early evidence that Nkarta’s Car-NK cells work – with a relatively clean safety profile to boot.
Key data reveals for the small players
Praxis, Proqr and Nordic Nanovector are awaiting important data.
Roche U-turns and Adaptimmune wins
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
Fate delivers, up to a point
The first human data from the Car-NK project FT596 are impressive – but not impressive enough for a company worth $9bn.
Fate looks to justify its $9bn valuation
The glacial development of Fate’s anti-CD19 Car-NK therapy FT596 could yield real data at last.